Home / Business and Economy / Eris Lifesciences Stock Plummets Amidst HALMED Inspection
Eris Lifesciences Stock Plummets Amidst HALMED Inspection
21 Apr
Summary
- HALMED inspected Swiss Parenterals' manufacturing facilities in Ahmedabad.
- Non-compliance observations were noted for two injectable units.
- Business operations impact is minimal; product pipeline commercialization may delay.
Eris Lifesciences experienced a significant stock decline of 4.95%, reaching Rs 1,362, subsequent to an inspection by HALMED at its wholly-owned subsidiary, Swiss Parenterals. The inspection, conducted from March 9 to 13, 2026, focused on manufacturing facilities in Ahmedabad, Gujarat, specifically Unit-1 for general liquid and dry powder injectables and Unit-2 for betalactam dry powder injectables.
Following the review, HALMED issued a list of non-compliance observations for both units. Eris Lifesciences indicated that these observations are procedural and necessitate improvements to align with good manufacturing practice (GMP) guidelines. The company plans to implement remediation measures and corrective action plans, seeking a follow-up inspection.
While Eris Lifesciences anticipates minimal disruption to its current business operations, there may be delays in the commercialization of its EU-CDMO product pipeline. The company reported a 19.05% increase in consolidated net profit to Rs 99.72 crore in Q3 FY26.
